Cargando…

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects

BACKGROUND: Dapagliflozin inhibits the sodium‐glucose–linked transporter 2 in the renal proximal tubule, thereby promoting glycosuria to reduce hyperglycemia in type 2 diabetes mellitus. Because these patients may require loop diuretics, and sodium‐glucose–linked transporter 2 inhibition causes an o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilcox, Christopher S., Shen, Wen, Boulton, David W., Leslie, Bruce R., Griffen, Steven C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850181/ https://www.ncbi.nlm.nih.gov/pubmed/29440005 http://dx.doi.org/10.1161/JAHA.117.007046

Ejemplares similares

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
por: Heerspink, H J Lambers, et al.
Publicado: (2013)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide
por: Zhao, Yongxiang, et al.
Publicado: (2022)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B
por: Hampel, Philip, et al.
Publicado: (2018)

Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action
por: Shah, Salim, et al.
Publicado: (2017)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma
por: Kuang, Haoyu, et al.
Publicado: (2017)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Loop Diuretics in Clinical Practice
por: Oh, Se Won, et al.
Publicado: (2015)

Novel Intranasal Loop Diuretic
por: Esque, Benjamin, et al.
Publicado: (2023)

Trimethylamine-N-Oxide: The Link Between Loop Diuretics and Cardiovascular Outcomes?
por: Adel, Fadi W., et al.
Publicado: (2021)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Ototoxic effects and mechanisms of loop diuretics
por: Ding, Dalian, et al.
Publicado: (2016)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

Bumetanide: Metabolic alkalosis: case report
Publicado: (2021)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin
por: Furuya, Futoshi, et al.
Publicado: (2022)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
por: Ansary, Tuba M., et al.
Publicado: (2019)

Loop diuretics association with Alzheimer’s disease risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
por: Tahrani, Abd A., et al.
Publicado: (2011)

Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
por: Charaya, Kristina, et al.
Publicado: (2022)

Bumetanide Exposure Association with Alzheimer’s Disease Risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
por: Chiba, Yumiko, et al.
Publicado: (2016)

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
por: Shin, Seok Joon, et al.
Publicado: (2016)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Mutagenic Mapping of the Na-K-Cl Cotransporter for Domains Involved in Ion Transport and Bumetanide Binding
por: Isenring, Paul, et al.
Publicado: (1998)

Loop Diuretic Administration in Patients with Acute Heart Failure and Reduced Systolic Function: Effects of Different Intravenous Diuretic Doses and Diuretic Response Measurements
por: Ruocco, Gaetano, et al.
Publicado: (2019)

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
por: Reilly, Timothy P., et al.
Publicado: (2014)

Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review
por: Gul, Wajiha, et al.
Publicado: (2021)

Off-Label Use of Bumetanide for Brain Disorders: An Overview
por: Kharod, Shivani C., et al.
Publicado: (2019)

Bumetanide for autism: Open‐label trial in six children
por: Fernell, Elisabeth, et al.
Publicado: (2021)

Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel
por: Kaila, Kai, et al.
Publicado: (2022)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
por: Zanoli, L., et al.
Publicado: (2015)

Analgesic effect of intrathecal bumetanide is accompanied by changes in spinal sodium-potassium-chloride co-transporter 1 and potassium-chloride co-transporter 2 expression in a rat model of incisional pain
por: He, Yanbing, et al.
Publicado: (2014)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mvfkajjobuhldeo302ivdvevbt